Cancer Prevention and Anticancer Claims: From Lactoferrin and Dietary Myths to Screening and Treatment

Cancer Prevention and Anticancer Claims: A Complete Evidence-Based Guide

The Bottom Line in One Sentence

When evaluating any “anticancer” claim, first ask whether it has actually improved important clinical outcomes in human cancer patients. Evidence from cells or animals, changes in immune markers, effects on precancerous lesions, or relief of treatment side effects should not be mistaken for evidence that cancer has been cured. This is also the fundamental boundary Professor Lin repeatedly emphasized in his original writings. PMID: 24867408

Lactoferrin: Supportive Uses Are Not Cancer Treatment

Professor Lin’s original article noted that no clinical study had shown lactoferrin to directly treat or cure cancer. The studies included in the ECU continue to support this boundary: most materials described as “anticancer” evidence concern mechanisms, biological activity, or preclinical research and cannot be directly translated into efficacy against tumors in humans. PMID: 35264972

A human trial of oral bovine lactoferrin reported inhibition of colorectal polyp growth. Polyps, however, are not the same as a diagnosed malignant tumor, so this finding cannot be promoted as evidence that lactoferrin treats cancer. PMID: 24867408

Lactoferrin has also been studied for anemia in cancer patients receiving chemotherapy. One study found oral lactoferrin to have effects comparable to intravenous iron. This use addresses treatment-related anemia; it does not eradicate cancer cells. PMID: 20647390

The most accurate conclusion, therefore, is not that “lactoferrin has no biological effects whatsoever,” but that “current human evidence does not show that it directly treats cancer.” This distinction preserves the research findings while preventing supportive care from being presented as anticancer therapy.

Causes of Cancer: Intrinsic Errors and External Risks Coexist

Cancer arises through the accumulation of somatic mutations, including replication errors that cannot be completely avoided when cells divide. This does not mean, however, that all cancers are merely a matter of luck or that prevention has no value. PMID: 28336671

Biological risks accumulate with age, while environmental exposures such as smoking also add to the carcinogenic burden. It can therefore be true both that “cancer cannot be prevented with absolute certainty” and that “some cancer risks can be reduced.” PMID: 37467337

A healthy lifestyle cannot guarantee that a person will never develop cancer, but it remains a reasonable strategy for reducing modifiable risks. If cancer does occur, early detection and appropriate treatment can still offer a chance of cure for some cancers. PMID: 41141307

Vague “detoxification” slogans must not replace attention to specific exposures. Residential radon exposure has a positive dose-response relationship with lung cancer, secondhand smoke raises lung cancer risk among people who do not smoke, and long-term outdoor air pollution has a consistent epidemiological association with lung cancer risk. PMID: 15613366

Diet and Supplements: Association Is Still Far from Therapeutic Efficacy

Certain foods may contain biologically active compounds, but “showing an effect in vitro” is not the same as “treating cancer when eaten.” Sulforaphane has anticancer-related mechanisms and research potential, but it cannot yet be described as an established anticancer treatment in humans. PMID: 42346421

In in vitro digestion studies, the sweet potato protein sporamin does not necessarily lose all activity. Reconsidered in light of today’s literature, the direction of this evidence differs from earlier categorical inferences; this reflects the evolution of science. These findings still do not demonstrate that eating sweet potatoes prevents or treats cancer in humans. PMID: 25473492

Coffee consumption has an observational association with lower overall cancer incidence and mortality, but this does not establish that coffee causally prevents every type of cancer. PMID: 28746796

Low-carbohydrate or ketogenic diets have not been shown to safely and effectively prevent or treat all cancers. Some cancer types have produced early research signals, but these require confirmation in higher-level trials. This is the more accurate characterization now that the literature has been updated. PMID: 42032215

Higher total dietary carbohydrate intake has not been shown to increase breast cancer recurrence; the more apparent protective association was observed with fiber. It is therefore inappropriate to treat every starch or carbohydrate as something that “feeds cancer cells.” PMID: 35220083

The harms of alcohol cannot be dismissed on the grounds that “many people drink.” Reassessment using today’s body of synthesized evidence shows that alcohol is associated with increased risks of multiple cancers and with dose-response relationships. This direction differs from the rhetorical questioning in the article. PMID: 25422909

Immunity and Cancer-Cell Dormancy: A Double-Edged Role Cannot Be Reduced to Slogans

The immune system can either suppress or facilitate cancer metastasis. This dual role, however, does not justify the conclusion that mushrooms, algae, or every product claiming to “boost immunity” will accelerate metastasis in humans; clinical evidence remains insufficient. PMID: 42147231

Cancer-cell dormancy is a genuine and active field of research. Dormant cells may evade conventional treatments that primarily target dividing cells, then reactivate later and contribute to recurrence or metastasis. PMID: 42271048

The concept discussed in Professor Lin’s earlier article—“awakening” dormant cells and then killing them—is indeed one line of research. As the literature has developed, “inducing and safely maintaining dormancy” has also become a formal research strategy. This represents scientific evolution; it does not retroactively attribute later advances to the position Professor Lin held at the time. PMID: 41935089

As for the popular claim that particular foods can make cancer cells “sleep,” current research in nutritional oncology and cancer-cell dormancy provides no actionable evidence of efficacy in humans. PMID: 41901058

Screening: Detecting a Signal Is Not the Same as Reducing Mortality

Circulating tumor cells and liquid biopsy are valuable research tools. Key questions remain unresolved, however, including their sensitivity for precancerous lesions, consistency of validation across platforms, and ability to reduce mortality. They therefore cannot yet be presented as reliable cancer screening tests for the general population. PMID: 42403089

Subsequent CancerSEEK research has progressed to prospective feasibility assessment in people without a prior cancer diagnosis, updating the research stage described in the earlier article. Completing a large feasibility study, however, is still not equivalent to proving that population-wide screening improves survival. PMID: 32345712

Cancer statistics must also distinguish among total case counts, crude rates, and age-standardized rates. Much of the global increase in cancer cases is related to population growth and aging. Age standardization is intended to remove differences in population age structure; it is incorrect to say that an older population necessarily drives the standardized rate lower. PMID: 27918777

County-level melanoma data suggest that diagnostic scrutiny may increase incidence figures, but this ecological association cannot establish that the entire increase is caused by diagnosis. Ultraviolet-related exposure remains a risk factor that cannot be disregarded. PMID: 15617990

Treatment Decisions Must Reflect Cancer Type, Stage, and Individual Circumstances

Cancer is not a single disease, and conventional treatment is not limited to chemotherapy. Surgery, radiotherapy, medication, immunotherapy, active surveillance, and supportive care must be selected according to cancer type, subtype, stage, physical condition, and the patient’s goals. Outcomes in certain lymphoma subtypes can be improved through guideline-concordant treatment; the experience of a single celebrity or individual case cannot replace subtype-specific evidence. PMID: 40970334

Observational research associates replacing conventional cancer treatment with unproven alternative therapies with a higher risk of death. This does not reject all forms of adjunctive care; it warns against delaying treatments supported by evidence of efficacy. PMID: 28922780

For some low-risk prostate cancers, active surveillance is a legitimate clinical option. It is a medically supervised strategy with defined eligibility and follow-up, not a decision to leave every cancer untreated. PMID: 36225285

Evidence on HIPEC has also become more differentiated as science has evolved. HIPEC cannot be declared uniformly effective or ineffective across all cancer types. A randomized colorectal cancer trial found no overall survival benefit from adding HIPEC, while research signals remain in some selected populations. PMID: 33476595

More short-term studies of interventional thermal ablation are now available in selected patients with early breast cancer, but long-term comparative evidence remains insufficient to establish a routine role. The more accurate update is therefore not that “no research exists,” but that thermal ablation “has not yet been shown to be superior to standard surgery.” PMID: 42322704

Hydrogen research likewise requires precise interpretation. The abstract of a relevant small study did report survival outcomes, so the earlier article’s statement that these were “not reported” differs from what can be verified today. Nevertheless, the study design remains insufficient to demonstrate that hydrogen caused an improvement in survival, much less to support claims that it can “eliminate terminal cancer.” PMID: 30542740

How to Use This Evidence

“Consistent with the literature” means that an article’s central direction is supported by current evidence. “Partially consistent” means that the direction is reasonable, but the wording, scope of application, or strength of causal inference must be narrowed. “Insufficient evidence” does not mean that ineffectiveness has been proved; it means that no definitive conclusion can currently be drawn. “Literature updated” or “contrary to the literature” reflects reassessment using higher-level evidence available today and does not rewrite Professor Lin’s original text or historical position.

Actual medical decisions should integrate the level of evidence, cancer type, stage, treatment goals, and individual risks, with evaluation by a healthcare team familiar with the patient’s condition. No supplement, diet, or emerging technology should replace diagnosis and treatment merely because it is labeled “anticancer.”